logo

For the Inventor, By the Inventor

Paris, France

Cellectis


USPTO Granted Patents = 97



Trademarks = 4

Forward Citations = 412

Loading Chart...
Loading Chart...

79 inventors (with patents filed for the assignee):

goldMedal Philippe Duchateau (43 out of 52 patents)

silverMedal Laurent Poirot (35 out of 35 patents)

bronzeMedal Roman Galetto (20 out of 25 patents)

4.  Julianne Smith (19 out of 21 patents)

5.  Julien Valton (16 out of 19 patents)

6.  Andrew M Scharenberg (16 out of 44 patents)

7.  Agnes Gouble (12 out of 12 patents)

8.  Alexandre Juillerat (12 out of 19 patents)

9.  Stephanie Grosse (9 out of 9 patents)

10.  Cecile Mannioui (8 out of 8 patents)

11.  Jean-Pierre Cabaniols (8 out of 8 patents)

12.  David Sourdive (7 out of 7 patents)

13.  Jean-Charles Epinat (7 out of 12 patents)

14.  André Choulika (6 out of 10 patents)

15.  Cécile Schiffer-Mannioui (6 out of 6 patents)


Core Competencies:
Gene Insertion
Chimeric Antigen Receptors
T Cell Engineering
Immunotherapy
CRISPR Technology
Cancer Treatment
Allogeneic Transplantation
Immune Cell Therapy
RNA-guided Cas Nuclease
Tumor Microenvironment
Dietary Fiber Enhancement
Plant Genetic Engineering

97 patents:

1. 12391933 - Targeted gene insertion for improved immune cells therapy (2025-08-19),
2. 12365733 - Method for improving production of car T cells (2025-07-22),
3. 12252699 - Method for generating t-cells compatible for allogenic transplantation (2025-03-18),
4. 12221478 - Targeted gene integration of CRS inhibitor genes for improved immune cells therapy (2025-02-11),
5. 12209125 - Targeted gene integration of NK inhibitors genes for improved immune cells therapy (2025-01-28),
6. 12171820 - Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment (2024-12-24),
7. 12144825 - Cellular immunotherapy for repetitive administration (2024-11-19),
8. 12012607 - Engineering wheat with increased dietary fiber (2024-06-18),
9. 11987639 - Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy (2024-05-21),
10. 11959091 - Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system (2024-04-16),
11. 11919961 - CD123 specific chimeric antigen receptors for cancer immunotherapy (2024-03-05),
12. 11903968 - Engineered immune cells resistant to tumor microenvironment (2024-02-20),
13. 11891614 - Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy (2024-02-06),
14. 11873511 - Targeted gene insertion for improved immune cells therapy (2024-01-16),
15. 11820996 - Method for generating T-cells compatible for allogenic transplantation (2023-11-21),
Cellectis is a biotechnology company that specializes in gene editing and the development of innovative CAR-T cell therapies for cancer treatment. With headquarters in Paris, France, and offices in New York, USA, Cellectis aims to revolutionize the field of immuno-oncology by providing highly personalized and off-the-shelf gene-edited CAR-T therapies. Their advanced technologies, such as TALEN® and MegaTAL™, enable precise and efficient gene modifications, offering new possibilities for the treatment of various cancers.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
97 Patents

#71 in Paris

#273 in France

#7,759 in the World

...
Paris, France

Cellectis

Forward Citations = 412

79 inventors:

goldMedal Philippe Duchateau (43 out of 52 patents)

silverMedal Laurent Poirot (35 out of 35 patents)

bronzeMedal Roman Galetto (20 out of 25 patents)

4.  Julianne Smith (19 out of 21 patents)

5.  Julien Valton (16 out of 19 patents)

Please report any incorrect information to support@idiyas.com
Loading…